CRISPR Therapy Lowers Cholesterol for Over a Year

A novel CRISPR-based gene editing therapy has demonstrated the ability to significantly reduce cholesterol levels in participants for a duration of at least 12 months. The findings, published online on September 1, 2026, in the journal Nature, stem from a small clinical trial that specifically targeted liver proteins involved in the regulation of lipid levels. This therapeutic approach represents a potential breakthrough in managing hypercholesterolemia, a condition characterized by abnormally high levels of cholesterol in the blood, which is a major risk factor for cardiovascular diseases.

The therapy utilizes CRISPR gene editing technology to modify the genes responsible for producing specific proteins in the liver. These proteins play a crucial role in how the body processes and regulates cholesterol. By altering the genetic instructions for these proteins, the therapy aims to achieve a sustained reduction in harmful cholesterol, such as low-density lipoprotein (LDL) cholesterol, and potentially increase beneficial high-density lipoprotein (HDL) cholesterol. The precise mechanism involves targeting genes that encode PCSK9, a protein that degrades LDL receptors in the liver, thereby increasing the liver's capacity to remove LDL cholesterol from the bloodstream. Other targets may include genes involved in triglyceride synthesis or HDL production.

This study involved a limited number of participants, and the long-term efficacy and safety profile are still under investigation. However, the sustained reduction in cholesterol levels observed for over a year post-treatment is a highly encouraging result. Previous treatments for high cholesterol, such as statins, typically require daily medication and can have side effects. Gene editing therapies, if proven safe and effective, could offer a one-time or infrequent treatment option with potentially more durable effects. The research team is likely planning larger clinical trials to further validate these findings, assess a wider range of patient populations, and monitor for any potential off-target effects of the gene editing process. The implications for cardiovascular health could be substantial, potentially reducing the incidence of heart attacks, strokes, and other related conditions.

The development of this CRISPR therapy builds upon years of research in gene editing and lipid metabolism. The ability to precisely edit DNA sequences offers a powerful tool for addressing genetic predispositions to diseases like hypercholesterolemia. While the technology is still in its early stages for therapeutic applications, successful trials like this one pave the way for a new era of medicine where genetic disorders can be treated at their root cause. The doi for the publication is 10.1038/d41586-026-02740-w, and the research was published in Nature.